Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (1005)	2/1/1998 7:12:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 1359

Tomorrow's Barron's has three articles suggesting AHP is in talks with PNU. Details at home.att.net in WSJ Table under GLX/SBH Merger section.

To: Pancho Villa who wrote (1005)	2/1/1998 2:59:00 PM
From: KurtVedder	Read Replies (1) \| Respond to of 1359

<<With all due respect for Neuro, be aware of the fact that the track record of most newsletters isn't that great and that there is more at stake here than just knowing or seemingly knowing the technical side. As far as IPIC is concerned, Neuro followers are still loosing on this one.>> Newsletters are just that. NEWSletters. They are there to provide information for the investor to analyze and then decide if he/she wishes to purchase the stock. If the news reported by the newsletter is thorough and accurate then it should be deemed an outstanding newsletter. In the case of Neuroinvestment NEWSletter, they have consistently provided excellent information regarding, among other neuro companies, IPIC. If someone purchases a stock because a newsletter says to then they have a lot to learn. Neuroinvestment is a fabulous resource for thoroughly understanding what you are buying. It, as well as all other newsletters, should not be judged on the stock performance of the companies they cover but rather on the wealth of information they provide. Plus, in the long run (which is the only way in which biotech's should be invested), I am confident that Neuroinvestment will outperform most, if not all, other newsletters in the field.